• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    RedChip Launches 'Small Stocks, Big Money' Podcast

    8/2/23 12:45:00 PM ET
    $BFRG
    $LTRN
    $RVPH
    $STSS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BFRG alert in real time by email

    New podcast series shines a spotlight on undervalued small-cap and microcap stocks

    ORLANDO, FL / ACCESSWIRE / August 2, 2023 / RedChip Companies, a renowned international investor relations firm specializing in microcap and small-cap companies,announce the launch of its much-anticipated podcast series, "Small Stocks, Big Money."

    Hosted by RedChip CEO Dave Gentry and Associate Director Barrett Boone, the "Small Stocks, Big Money" podcast aims to offer a first-hand look at undiscovered small-cap and microcap stocks before they catch the attention of bigger Wall Street players. The series features in-depth interviews with executives from some of the top names in smaller cap stocks, providing listeners with an insider perspective they won't find anywhere else.

    "Small Stocks, Big Money is not just a podcast. It's a mission to empower everyday investors by providing them with the knowledge and insights they need to discover potentially lucrative investment opportunities," said Gentry. "We're taking our 30 plus years of experience in the microcap space and sharing it with the world. Our vision is to shed light on these lesser-known companies that hold the potential to deliver substantial returns."

    Episodes of "Small Stocks, Big Money" are now available for streaming on major platforms including Spotify, Amazon, and Apple.

    The debut episodes of "Small Stocks, Big Money" feature Sharps Technology (NASDAQ:STSS), BullFrog AI (NASDAQ:BFRG), Zomedica (NYSE:ZOM), Lantern Pharma (NASDAQ:LTRN), and Reviva Pharmaceuticals (NASDAQ:RVPH).

    Listeners are encouraged to subscribe to the series to stay up-to-date with the latest episodes. Each installment promises to be a deep dive into the fast-paced world of microcap investing, offering unique insights that could shape the future of your investment portfolio.

    The "Small Stocks, Big Money" podcast series takes inspiration from the book of the same name written by Gentry. Published by Wiley, the book offers a unique perspective on microcap investing through a series of insightful interviews with small stock superstars. It provides readers with key lessons learned from successful investments and helps them understand how to discover promising companies, develop solid investment strategies, and navigate the risks associated with smaller companies. This wealth of knowledge now extends to the podcast, making it an invaluable resource for anyone interested in the world of small stocks and big money.

    About RedChip Companies

    RedChip Companies, an Inc. 5000 company, is an international investor relations, media, and research firm focused on microcap and small-cap companies. For 30 years, RedChip has delivered concrete, measurable results for its clients. Our newsletter, the RedChip Money Report is delivered online weekly to 60,000 investors. RedChip has developed the most comprehensive service platform in the industry for microcap and small-cap companies. These services include the following: a worldwide distribution network for its stock research; retail and institutional roadshows in major U.S. cities; outbound marketing to stock brokers, RIAs, institutions, and family offices; a digital media investor relations platform that has generated millions of unique investor views; investor webinars and group calls; a television show, "The RedChip Money Report," which airs weekly on Bloomberg US; TV commercials in local and national markets; corporate and product videos; website design; and traditional investor relation services, which include press release writing, development of investor presentations, quarterly conference call script writing, strategic consulting, capital raising, and more.

    To learn more about RedChip's products and services, please visit:

    https://www.redchip.com/corporate/investor_relations

    "Discovering Tomorrow's Blue Chips Today"™

    Contact:

    Dave Gentry
    RedChip Companies Inc.
    1-800-RED-CHIP (733-2447)
    Or 407-491-4498
    [email protected]

    SOURCE: RedChip



    View source version on accesswire.com:
    https://www.accesswire.com/771825/RedChip-Launches-Small-Stocks-Big-Money-Podcast

    Get the next $BFRG alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BFRG
    $LTRN
    $RVPH
    $STSS

    CompanyDatePrice TargetRatingAnalyst
    Reviva Pharmaceuticals Holdings Inc.
    $RVPH
    3/5/2026Buy → Hold
    D. Boral Capital
    Reviva Pharmaceuticals Holdings Inc.
    $RVPH
    9/29/2025$2.00Buy
    Chardan Capital Markets
    Reviva Pharmaceuticals Holdings Inc.
    $RVPH
    9/20/2023$12.00Buy
    ROTH MKM
    Reviva Pharmaceuticals Holdings Inc.
    $RVPH
    6/8/2023$17.00Speculative Buy
    The Benchmark Company
    Zomedica Corp.
    $ZOM
    1/6/2023$6.00Buy
    Dawson James
    Lantern Pharma Inc.
    $LTRN
    3/11/2022$34.00 → $36.00Buy
    HC Wainwright & Co.
    Reviva Pharmaceuticals Holdings Inc.
    $RVPH
    1/24/2022$10.00Buy
    HC Wainwright & Co.
    Lantern Pharma Inc.
    $LTRN
    11/2/2021$32.00 → $34.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $BFRG
    $LTRN
    $RVPH
    $STSS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Falconx Holdings Ltd sold $1,490,755 worth of shares (769,320 units at $1.94) and exercised 461,538 in-the-money shares at a strike of $0.00 (SEC Form 4)

    4 - Sharps Technology Inc. (0001737995) (Issuer)

    2/13/26 4:45:04 PM ET
    $STSS
    Medical/Dental Instruments
    Health Care

    New insider Falconx Holdings Ltd claimed ownership of 769,230 shares (SEC Form 3)

    3 - Sharps Technology Inc. (0001737995) (Issuer)

    2/13/26 4:10:05 PM ET
    $STSS
    Medical/Dental Instruments
    Health Care

    Large owner Saba Capital Management, L.P. sold $86,371 worth of shares (37,182 units at $2.32) (SEC Form 4)

    4 - Sharps Technology Inc. (0001737995) (Issuer)

    1/20/26 5:55:14 PM ET
    $STSS
    Medical/Dental Instruments
    Health Care

    $BFRG
    $LTRN
    $RVPH
    $STSS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Reviva Pharmaceuticals downgraded by D. Boral Capital

    D. Boral Capital downgraded Reviva Pharmaceuticals from Buy to Hold

    3/5/26 8:53:11 AM ET
    $RVPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chardan Capital Markets initiated coverage on Reviva Pharmaceuticals with a new price target

    Chardan Capital Markets initiated coverage of Reviva Pharmaceuticals with a rating of Buy and set a new price target of $2.00

    9/29/25 9:59:06 AM ET
    $RVPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ROTH MKM initiated coverage on Reviva Pharmaceuticals with a new price target

    ROTH MKM initiated coverage of Reviva Pharmaceuticals with a rating of Buy and set a new price target of $12.00

    9/20/23 7:22:47 AM ET
    $RVPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BFRG
    $LTRN
    $RVPH
    $STSS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Sharps Technology and The Tie Announce Strategic Collaboration to Advance Institutional Participation in the Solana Ecosystem

    NEW YORK, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. ("STSS" or the "Company") (NASDAQ:STSS), a medical device company with a Solana digital asset treasury strategy, and The Tie, Inc. ("The Tie"), the leading provider of institutional-grade digital asset analytics, compliant communications, and infrastructure services, today announced a strategic collaboration to strengthen Solana's institutional infrastructure and expand institutional access to the ecosystem. Under the collaboration, STSS will delegate a portion of its SOL treasury holdings, currently more than 2 million SOL, to Stakin by The Tie, which operates non-custodial validator infrastructure across 40+ proof-o

    2/25/26 9:00:00 AM ET
    $STSS
    Medical/Dental Instruments
    Health Care

    Diality Appoints Peter Donato as Chief Financial Officer

    Life sciences veteran brings private and public sector expertise to company in midst of growth trajectory Diality Inc., a medical device company that has developed the Moda-flx™ Hemodialysis System, today announced it has named Peter Donato as its chief financial officer. Donato joins the company as it continues to enroll patients in the PRESCRIBE Diality Home Hemodialysis Clinical Trial of its Moda-flx Hemodialysis System while preparing for a limited market release in 2027. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260224064413/en/Diality CFO Peter Donato. Donato joins Diality with nearly 35 years of financial leadershi

    2/24/26 7:05:00 AM ET
    $MYGN
    $STIM
    $TFX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Medical/Dental Instruments
    Pharmaceuticals and Biotechnology

    EGFR-NSCLC Market to Observe Stunning Growth at a CAGR of 9.6% During the Forecast Period (2025-2034) | DelveInsight

    The EGFR-NSCLC market is expected to grow owing to the approval of new agents such as Zipalertinib (Cullinan Oncology/Taiho Pharma), Ivonescimab (Akeso Biopharma/Summit Therapeutics), Sacituzumab Tirumotecan (Merck/Kelun-Biotech), Izalontamab Brengitecan (Bristol-Myers Squibb), Firmonertinib (ArriVent BioPharma), and others in frontline and combination settings, rising therapy costs, and increasing testing rates that enable the identification of more patients with EGFR alterations. LAS VEGAS, Feb. 11, 2026 /PRNewswire/ -- DelveInsight's EGFR-NSCLC Market Insights report includes a comprehensive understanding of current treatment practices, EGFR-NSCLC emerging drugs, market share of individua

    2/11/26 5:31:00 PM ET
    $ABBV
    $AVBP
    $BDTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    $BFRG
    $LTRN
    $RVPH
    $STSS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Ruemler Timothy James increased direct ownership by 294% to 40,218 units (SEC Form 4)

    4 - Sharps Technology Inc. (0001737995) (Issuer)

    8/26/25 9:45:47 PM ET
    $STSS
    Medical/Dental Instruments
    Health Care

    Chief Financial Officer Crescenzo Andrew R. bought $256,400 worth of Option (40,000 units at $6.41) (SEC Form 4)

    4 - Sharps Technology Inc. (0001737995) (Issuer)

    8/26/25 9:24:34 PM ET
    $STSS
    Medical/Dental Instruments
    Health Care

    Director Monroe Jason L. bought $512,800 worth of Option (80,000 units at $6.41) (SEC Form 4)

    4 - Sharps Technology Inc. (0001737995) (Issuer)

    8/26/25 9:24:36 PM ET
    $STSS
    Medical/Dental Instruments
    Health Care

    $BFRG
    $LTRN
    $RVPH
    $STSS
    SEC Filings

    View All

    Reviva Pharmaceuticals Holdings Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits

    8-K - REVIVA PHARMACEUTICALS HOLDINGS, INC. (0001742927) (Filer)

    3/5/26 8:00:13 AM ET
    $RVPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sharps Technology Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Leadership Update

    8-K - Sharps Technology Inc. (0001737995) (Filer)

    2/23/26 4:15:27 PM ET
    $STSS
    Medical/Dental Instruments
    Health Care

    Bullfrog AI Holdings Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits

    8-K - BullFrog AI Holdings, Inc. (0001829247) (Filer)

    2/20/26 8:28:41 PM ET
    $BFRG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BFRG
    $LTRN
    $RVPH
    $STSS
    Leadership Updates

    Live Leadership Updates

    View All

    Diality Appoints Peter Donato as Chief Financial Officer

    Life sciences veteran brings private and public sector expertise to company in midst of growth trajectory Diality Inc., a medical device company that has developed the Moda-flx™ Hemodialysis System, today announced it has named Peter Donato as its chief financial officer. Donato joins the company as it continues to enroll patients in the PRESCRIBE Diality Home Hemodialysis Clinical Trial of its Moda-flx Hemodialysis System while preparing for a limited market release in 2027. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260224064413/en/Diality CFO Peter Donato. Donato joins Diality with nearly 35 years of financial leadershi

    2/24/26 7:05:00 AM ET
    $MYGN
    $STIM
    $TFX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Medical/Dental Instruments
    Pharmaceuticals and Biotechnology

    Lantern Pharma Announces Appointment of Dr. Lee Schalop to Board of Directors

    Seasoned Biotech Executive & Wall Street Analyst Brings Deep Expertise in Precision Neurooncology, Biopharma Partnering and Clinical Development Lantern Pharma Inc. (NASDAQ:LTRN), a clinical-stage biopharmaceutical company using artificial intelligence, machine learning and genomic data to transform the cost, pace and timeline of oncology drug discovery and development, today announced the appointment of Lee T. Schalop, MD, to its Board of Directors. Dr. Schalop brings over two decades of combined experience in biotechnology leadership and financial markets, with particular expertise in precision neurooncology and clinical development. Most notably, he co-founded and was a key member

    7/28/25 8:00:00 AM ET
    $CMRX
    $LTRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BullFrog AI Issues Letter to Stockholders

    GAITHERSBURG, Md., Dec. 27, 2024 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ:BFRG, BFRGW)) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, issued a letter to stockholders from its CEO Vin Singh. Dear Fellow Stockholders, As the year comes to a close, I want to extend my deepest gratitude for your unwavering support and belief in our mission to revolutionize drug development. Your commitment fuels our drive to innovate and achieve transformational milestones. In thinking back on this past year, it is evident that 2024 wa

    12/27/24 8:00:00 AM ET
    $BFRG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BFRG
    $LTRN
    $RVPH
    $STSS
    Financials

    Live finance-specific insights

    View All

    Lantern Pharma Reports Third Quarter 2025 Financial Results and Provides Business Updates

    Transformational Quarter Marked by Clinical Validation, Regulatory Progress, and Strategic Momentum in Commercial AI Platform Launch LP-184 Phase 1a clinical trial results demonstrate all primary endpoints achieved with 48% clinical benefit rate in evaluable cancer patients at or above therapeutic dose threshold; marked tumor reductions observed in patients with DNA damage repair mutations including CHK2, ATM, and STK11/KEAP1 alterations. FDA Type C meeting completed, providing regulatory guidance and pathway clarity for Starlight Therapeutics' planned pediatric CNS cancer trial in Atypical Teratoid Rhabdoid Tumor (ATRT) and confirming spironolactone combination strategy. LP-300 pr

    11/13/25 8:30:00 AM ET
    $LTRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lantern Pharma to Report Third Quarter 2025 Operating & Financial Results on November 13th, 2025 at 9:00 a.m. ET

    Webcast to be held Thursday, November 13th, 9:00 a.m. ET, register for the webcast here, or at the link provided below. Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence ("AI") company developing targeted and transformative cancer therapies using its proprietary RADR® AI and machine learning ("ML") platform with multiple clinical stage drug programs, today announced that it will host its third quarter 2025 operating and financial results webcast on Thursday, November 13, 9:00 a.m. Eastern Time / 6:00 a.m. Pacific Time. Management intends to discuss the operating and financial results for the third quarter ended September 30, 2025 and provide guidance on upcoming milestones,

    11/6/25 8:00:00 AM ET
    $LTRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sharps Technology, Inc. Acquires Over 2 Million SOL, the Native Asset of Solana, the Fastest and Most Used Public Blockchain

    NEW YORK, Sept. 2, 2025 /PRNewswire/ -- Sharps Technology, Inc. (the "Company" or "Sharps Technology") (Nasdaq: "STSS" and "STSSW") today announced its first acquisition of Solana ("SOL") tokens as part of its digital asset treasury strategy under which the principal holding will be SOL, the native digital asset of the Solana blockchain. Funded from the Company's recent PIPE equity raise, Sharps Technology now holds over 2 million SOL, creating a SOL treasury currently valued north of $400M. Sharps Technology intends to provide regular updates on its SOL holdings and performan

    9/2/25 7:00:00 AM ET
    $STSS
    Medical/Dental Instruments
    Health Care

    $BFRG
    $LTRN
    $RVPH
    $STSS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Reviva Pharmaceuticals Holdings Inc.

    SC 13G/A - REVIVA PHARMACEUTICALS HOLDINGS, INC. (0001742927) (Subject)

    11/14/24 5:16:56 PM ET
    $RVPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Reviva Pharmaceuticals Holdings Inc.

    SC 13G - REVIVA PHARMACEUTICALS HOLDINGS, INC. (0001742927) (Subject)

    11/14/24 4:15:57 PM ET
    $RVPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Sharps Technology Inc.

    SC 13G/A - Sharps Technology Inc. (0001737995) (Subject)

    11/13/24 4:50:17 PM ET
    $STSS
    Medical/Dental Instruments
    Health Care